Article

A pilot study on the use of amikacin in neonates: Who should be monitored for ototoxicity?

Published in: Southern African Journal of Infectious Diseases
Volume 30 , issue 3, pages: 72–76

DOI: 10.1080/23120053.2015.1074432

Author(s): Deirdré EnglerDepartment of Pharmacy, South Africa, Natalie SchellackDepartment of Pharmacy, South Africa, Alida NaudeDiscipline of Speech- Language Pathology and Audiology, South Africa, Andries GousDepartment of Pharmacy, South Africa,

Keywords: amikacin, neonates, ototoxicity, pharmacokinetics,

Download full text Get new issue alerts

Abstract

Background: Aminoglycosides (AGs) cause irreversible hearing loss. The toxic effects of AGs are dose dependent and correlate with increasing drug serum concentrations.

« Nocardia mastoiditis in an African child

Experiences in the implementation of provider-initiated counselling and testing and linkage to HIV services at urban public sector health facilities in KwaZulu-Natal »

Article

A pilot study on the use of amikacin in neonates: Who should be monitored for ototoxicity?

Abstract

Get new issue alerts for Southern African Journal of Infectious Diseases

Latest news

Latest articles